ZA200200265B - Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances. - Google Patents

Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances.

Info

Publication number
ZA200200265B
ZA200200265B ZA200200265A ZA200200265A ZA200200265B ZA 200200265 B ZA200200265 B ZA 200200265B ZA 200200265 A ZA200200265 A ZA 200200265A ZA 200200265 A ZA200200265 A ZA 200200265A ZA 200200265 B ZA200200265 B ZA 200200265B
Authority
ZA
South Africa
Prior art keywords
substances
medicament
protective effect
cardiotoxic
toxic substances
Prior art date
Application number
ZA200200265A
Other languages
English (en)
Inventor
Zsuzsanna Rozsa
Julius Papp Gy
Dirk Thormaehlen
Harald Waldeck
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of ZA200200265B publication Critical patent/ZA200200265B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200200265A 1999-07-13 2002-01-11 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances. ZA200200265B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19932555A DE19932555A1 (de) 1999-07-13 1999-07-13 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Publications (1)

Publication Number Publication Date
ZA200200265B true ZA200200265B (en) 2003-03-26

Family

ID=7914519

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200265A ZA200200265B (en) 1999-07-13 2002-01-11 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances.

Country Status (28)

Country Link
US (1) US6906059B2 (fr)
EP (1) EP1200095B1 (fr)
JP (1) JP4824235B2 (fr)
KR (1) KR100738940B1 (fr)
CN (1) CN1267099C (fr)
AR (1) AR024476A1 (fr)
AT (1) ATE306926T1 (fr)
AU (1) AU782733B2 (fr)
BR (1) BR0012442A (fr)
CA (1) CA2377904C (fr)
CZ (1) CZ299070B6 (fr)
DE (2) DE19932555A1 (fr)
DK (1) DK1200095T3 (fr)
ES (1) ES2246874T3 (fr)
HK (1) HK1049116B (fr)
HU (1) HUP0202424A3 (fr)
IL (2) IL147604A0 (fr)
MX (1) MXPA02000411A (fr)
NO (1) NO329558B1 (fr)
NZ (1) NZ517130A (fr)
PL (1) PL198723B1 (fr)
RU (1) RU2268727C2 (fr)
SK (1) SK286020B6 (fr)
TR (1) TR200200053T2 (fr)
TW (1) TWI280880B (fr)
UA (1) UA73134C2 (fr)
WO (1) WO2001003699A1 (fr)
ZA (1) ZA200200265B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
PL367093A1 (en) * 2001-05-18 2005-02-21 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
JP4521185B2 (ja) * 2001-09-10 2010-08-11 テイボテク・フアーマシユーチカルズ・リミテツド ヘキサヒドロ−フロ［２，３−ｂ］フラン−３−オールの製造法
EP1468010A1 (fr) 2002-01-16 2004-10-20 Solvay Pharmaceuticals B.V. Composes de benzazepine de sels solides et leur utilisation dans la preparation de composes pharmaceutiques
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
CN100566719C (zh) 2003-11-18 2009-12-09 索尔瓦药物有限公司 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1827448A1 (fr) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Compositions pharmaceutiques comprenant des inhibiteurs nep, inhibiteurs du systeme de production de l'endotheline endogene et inhibiteurs de la reductase hmg coa
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
CA2643846A1 (fr) * 2006-02-27 2007-09-07 Targeted Molecular Diagnostics, Llc Procedes permettant de predire la toxicite cellulaire au cours d'un traitement avec des inhibiteurs de tyrosine kinasesnt avec des inhibiteurs de tyrosine kinases
WO2007102171A2 (fr) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Nouveaux sels de l'acide 1h-1-benzazépine-1-acétique, préparation de ceux-ci et composition pharmaceutique comprenant ceux-ci
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
JP3775780B2 (ja) * 1997-09-18 2006-05-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤の経口的バイオアベイラビリテイを向上させるための縮合イミダゾール誘導体
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Also Published As

Publication number Publication date
DK1200095T3 (da) 2005-11-14
WO2001003699A1 (fr) 2001-01-18
KR20020019514A (ko) 2002-03-12
IL147604A0 (en) 2002-08-14
NZ517130A (en) 2004-10-29
PL198723B1 (pl) 2008-07-31
AR024476A1 (es) 2002-10-02
IL147604A (en) 2006-12-31
JP2003504336A (ja) 2003-02-04
ES2246874T3 (es) 2006-03-01
HK1049116B (zh) 2006-12-08
PL353012A1 (en) 2003-10-06
BR0012442A (pt) 2002-04-02
CA2377904C (fr) 2009-03-24
KR100738940B1 (ko) 2007-07-12
MXPA02000411A (es) 2002-07-02
US20030040512A1 (en) 2003-02-27
SK286020B6 (sk) 2008-01-07
AU6157200A (en) 2001-01-30
CZ200252A3 (cs) 2002-08-14
TR200200053T2 (tr) 2002-05-21
US6906059B2 (en) 2005-06-14
CA2377904A1 (fr) 2001-01-18
TWI280880B (en) 2007-05-11
NO20020132L (no) 2002-03-12
EP1200095B1 (fr) 2005-10-19
DE19932555A1 (de) 2001-01-18
JP4824235B2 (ja) 2011-11-30
HK1049116A1 (en) 2003-05-02
ATE306926T1 (de) 2005-11-15
NO329558B1 (no) 2010-11-15
AU782733B2 (en) 2005-08-25
HUP0202424A3 (en) 2003-03-28
NO20020132D0 (no) 2002-01-11
CN1373666A (zh) 2002-10-09
HUP0202424A2 (hu) 2002-11-28
RU2268727C2 (ru) 2006-01-27
DE50011388D1 (de) 2006-03-02
UA73134C2 (en) 2005-06-15
CN1267099C (zh) 2006-08-02
SK142002A3 (en) 2002-06-04
EP1200095A1 (fr) 2002-05-02
CZ299070B6 (cs) 2008-04-16

Similar Documents

Publication Publication Date Title
ZA200200265B (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances.
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
HK1048969A1 (en) Dual droplet size printead.
ZA200200477B (en) 2-pyrazolin-5-ones.
ZA200005237B (en) Biocidal benzylbiphenyl derivatives.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
AU6923600A (en) Iv guard
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1051199A1 (en) New phenylpiperazines.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
ZA200203707B (en) Pharmaceutical combinations.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
ZA200201502B (en) Safety syringe.
ZA200110454B (en) Pharmaceutical complex.
MXPA01011285A (es) Derivados de tio-oxindol.
GB0029720D0 (en) I.S machine7544232001
ZA200204581B (en) Nitro-sulfobenzamides.
MXPA02002850A (es) Fungicidas.
HK1031254A1 (en) Tachogragh.
ZA200004224B (en) Protective shroud.
ZA200002670B (en) Safe.